TITLE

Schering and Bayer seal drug ownership agreement

AUTHOR(S)
Chynoweth, Emma
PUB. DATE
April 2007
SOURCE
ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site, where it will produce the drug for U.S. patients. Bayer Schering will have full control of the manufacturing and process technology and continue to employ the facility's workforce.
ACCESSION #
24889303

 

Share

Other Topics